Dr. Ilaria Palmisano's lab at Ohio State University focuses on understanding how the structure of DNA, specifically its 3D organization, affects the ability of nerves to regenerate after injuries. This research is crucial because nerve injuries can lead to long-lasting health issues and disabilities. By manipulating the molecular mechanisms involved in gene expression, the lab aims to develop new therapeutic strategies to enhance nerve repair and recovery.

Dr. Erik Musiek's lab at Washington University focuses on understanding how disruptions in circadian rhythms affect brain function and contribute to Alzheimer's Disease. The lab explores the role of specific proteins, called REV-ERBs, in regulating the activity of astrocytes, which are support cells in the brain. By manipulating these proteins, the goal is to find new therapeutic strategies to mitigate the damaging effects of Alzheimer's Disease on brain health.

Kelvin Y. Kwan's lab at Rutgers University focuses on investigating the epigenetic factors that contribute to hearing loss, particularly through the study of the CHD4 protein in the cochlea. The team explores how alterations in CHD4 affect hair cell identity and function, with the goal of uncovering mechanisms for hair cell maintenance and potential regeneration. This research could lead to novel therapies for treating various forms of hearing impairment.

Dr. Rocio Gomez-Pastor's lab at the University of Minnesota focuses on understanding how cognitive decline occurs in Huntington's disease, a neurodegenerative condition that affects movement as well as cognition. The lab studies the molecular mechanisms behind synaptic dysfunction in the brain's striatum region, particularly how disruptions in certain proteins impact cognitive performance in early stages of the disease. Insights gained may help identify therapeutic targets that can improve the quality of life for those affected.

Dr. Solange P Brown's lab at Johns Hopkins University studies how a brain region called the claustrum helps us make flexible decisions, especially under changing circumstances. They use animal models to investigate how the claustrum interacts with other brain areas critical for cognition, particularly when we need to learn from our past choices. By understanding these brain mechanisms better, the research aims to shed light on cognitive flexibility, which is often impaired in various neuropsychiatric disorders like schizophrenia and ADHD.

Dr. Danny Jj Wang's lab at the University of Southern California focuses on understanding how small vessel disease affects cognitive function and dementia through innovative imaging techniques. They are working to validate biomarkers that help identify these conditions, with a specific emphasis on diverse populations in Los Angeles. The lab is also exploring how the blood-brain barrier functions and can be assessed non-invasively using MRI technology, which could lead to new diagnostic tools for neurodegenerative diseases.

Dr. George W. Huntley's lab focuses on understanding the early cognitive impairments that occur in individuals with Parkinson's disease, specifically how these changes relate to the neurobiology of the brain. The team investigates a mouse model carrying a mutation linked to Parkinson's, exploring the role of cholinergic signaling and how it differs between male and female mice. The goal is to identify potential treatments for cognitive decline in Parkinson's patients and improve diagnosis tools.

Dr. Erica R. Glasper's research lab at Ohio State University focuses on understanding how social relationships impact mental and physical health. They study the effects of losing social connections, such as through loneliness, and explore the biological processes involved, particularly looking at inflammation and metabolic changes in the brain. By using California mice as a model, the lab aims to uncover potential interventions to improve health outcomes for individuals suffering from social isolation.

The research lab of Dr. Royce Mohan at the University of Connecticut focuses on understanding injuries to the cornea caused by chemical agents like sulfur mustard. They investigate the molecular changes that occur in response to these injuries, particularly how specific proteins are modified and how sensory nerve cells in the cornea are affected. This research aims to identify new biological markers and targets for improving recovery from such damage.

Dr. Arnold Kriegstein's research lab focuses on understanding how the human brain develops and how its complexity relates to neurodevelopmental diseases like autism and schizophrenia. The lab uses innovative technologies to study both human tissue and stem cells to unravel the diversity of neural cells and their roles in brain function. By creating detailed brain atlases of both humans and non-human primates, the lab aims to uncover the fundamental processes of brain development and evolutionary distinctions, ultimately improving therapeutic strategies for brain-related disorders.

Dr. Matthew Douglas Johnson's lab at the University of Minnesota focuses on improving deep brain stimulation (DBS) therapy for Parkinson's disease. The research aims to optimize stimulation settings in order to enhance motor control and address specific symptoms such as bradykinesia, rigidity, tremor, and postural instability. By using advanced technologies like microelectrode arrays and adaptive control algorithms, the lab seeks to develop personalized and responsive therapies for patients.

Dr. C. Daniel Salzman's lab at Columbia University focuses on understanding how the brain makes decisions and processes social information. They explore neural mechanisms involved in decision-making, especially in novel situations and when responding to social cues, using techniques like electrophysiology and behavioral assays. Research from this lab aims to shed light on the complexities of motivated behavior and emotional regulation, particularly in the context of psychiatric disorders.

Dr. Ilana Witten's research focuses on understanding why people behave differently in similar situations, a question that intersects both nature and nurture. By studying dopamine neurons in the brain, her lab investigates how individual differences arise from unique reward associations that each person develops in response to their environment. This research could enhance our understanding of neuropsychiatric diseases, which often manifest through these variations in behavior.

Dr. Catherine Jensen Pena's lab at Princeton University investigates how early life adversity (ELA) affects brain development and influences sensitivity to stress in later life. They explore the role of epigenetic changes, particularly in the chromatin structure of the brain, to understand the biological underpinnings of depression and anxiety. The lab uses innovative techniques and a mouse model to test how these changes may lead to mental health challenges like anxiety and depression.

Dr. Zhong Irene Wang's lab focuses on improving the diagnosis and treatment of epilepsy, particularly for patients who have not had success with traditional therapies. The lab uses advanced MR Fingerprinting technology to detect subtle brain abnormalities that are often missed in standard MRI scans. This cutting-edge approach aims to enhance surgical outcomes for patients suffering from resistant forms of epilepsy by combining imaging data with machine learning to develop personalized treatment plans.

Dr. Jun Li's lab focuses on understanding the role of a specific protein called EZH2 in diseases like Alzheimer's and Cerebral Amyloid Angiopathy. By studying the interactions between EZH2, a notable epigenetic modifier, and endothelial nitric oxide synthase (eNOS), the lab aims to uncover mechanisms of blood flow regulation, blood-brain barrier integrity, and cognitive function related to these diseases. The research uses mouse models to explore potential therapeutic strategies to mitigate cognitive decline and vascular dysfunction in dementia.

Dr. Vikas Kotagal's lab focuses on understanding and reducing the risk of falls in individuals with Parkinson's disease, particularly those experiencing cognitive impairments. They are investigating the effects of a drug called varenicline, which may enhance attention and improve walking performance, potentially leading to fewer falls. The lab combines clinical research with advanced imaging techniques to explore how brain function is linked to movement problems in Parkinson's patients.

Dr. Geoffrey Aguirre's lab at the University of Pennsylvania focuses on understanding how migraines and visual discomfort interact with perceptions of flickering light. They explore the brain's response to visual stimuli in people with and without migraines, using innovative technology to measure light exposure and analyze how this impacts sensory experience. The goal is to uncover the underlying neural mechanisms of photophobia and improve management strategies for those affected by migraines.

Dr. Meyer B. Jackson's lab at the University of Wisconsin-Madison examines how cells release signaling molecules through a process called exocytosis. They study the structures involved in this process, known as fusion pores, which regulate the release of neurotransmitters and hormones. By using innovative biophysical techniques, the lab seeks to understand the molecular mechanisms underlying exocytosis and how these processes are altered in various neurological and endocrine disorders.

Dr. Marc W. Slutzky's research focuses on improving gait and movement in stroke survivors using an innovative approach called MINT conditioning. This method aims to correct abnormal muscle activation patterns that negatively impact walking and quality of life. Ultimately, the goal is to develop a user-friendly, wearable device for home therapy that enhances rehabilitation efforts after a stroke.